RIVASTIGMINE PATCH 10 Strength — DIN 02479559
Active ingredient(s) See footnote 8 : Strength RIVASTIGMINE : 9.5 MG / 24 HOUR · PHARMASCIENCE INC 100 6111 Royalmount Ave Montreal Quebec Canada H4P 2T4 · Patch · wholesale supply in Canada
Health Canada status: DORMANT
What is RIVASTIGMINE PATCH 10?
RIVASTIGMINE PATCH 10 Strength contains Active ingredient(s) See footnote 8 : Strength RIVASTIGMINE : 9.5 MG / 24 HOUR. It is listed in the Health Canada Drug Product Database under DIN 02479559, held by PHARMASCIENCE INC 100 6111 Royalmount Ave Montreal Quebec Canada H4P 2T4, supplied as Patch for Transdermal administration. Health Canada currently lists it as dormant, status dated 31-Jul-2024. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A). This DIN is not currently being marketed in Canada, so it is sourced to order where a compliant route exists rather than held in stock.
What is RIVASTIGMINE PATCH 10 used for?
Symptomatic treatment of patients with mild to moderately severe dementia of the Alzheimer's type.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
How much does Rivastigmine cost around the world?
Rivastigmine is listed on 12 of the national price registers Nexara ingests. Each country publishes on a different basis, so figures are not comparable with one another — or with a Canadian wholesale price.
What a market publishes matters more than the number it publishes. Australia publishes a ex-manufacturer; Austria publishes a KVP (Kassenverkaufspreis); Bahrain publishes a retail (max). Comparing an ex-factory ceiling against a pharmacy public price tells you nothing about either, and comparing either against a Canadian landed cost tells you less.
| Market | Price basis published there | Brands | Packs listed |
|---|---|---|---|
| United States | acquisition | 7 | 66 |
| Austria | KVP (Kassenverkaufspreis) | 33 | 43 |
| Greece | producer price (ex-factory) | 22 | 22 |
| Saudi Arabia | public | 17 | 19 |
| Australia | ex-manufacturer | 4 | 14 |
| Czechia | max producer price (ex-factory) | 2 | 14 |
| United Kingdom | hospital | 8 | 8 |
| Luxembourg | reimbursement | 8 | 8 |
| South Africa | single exit price | 7 | 8 |
| Hungary | producer price (ex-factory) | 5 | 7 |
| Bahrain | retail (max) | 1 | 2 |
| Morocco | PPV (public price) | 2 | 2 |
213 pack listings across 116 brand entries and 11 price bases, refreshed 08 Sep 2026. Ranges span every Rivastigmine pack in that market, so a high figure is usually a larger pack rather than the same product.
Canada publishes no comparable public list price. For a delivered Canadian price on a licensed account, verify your licence — it takes about a minute.
Is there a generic Rivastigmine in Canada, and who makes it?
Every market authorization holder with a Canadian DIN for this molecule, and how many of their listings Health Canada currently shows as marketed.
18 holders have a Canadian DIN containing Rivastigmine, across 80 DINs, of which 28 are currently marketed. Marketed count is the number that matters: an approval that is not marketed cannot be bought.
| Market authorization holder | DINs | Marketed | Brand names | Position |
|---|---|---|---|---|
| JAMP PHARMA CORPORATION | 8 | 8 | JAMP RIVASTIGMINE, JAMP RIVASTIGMINE CAPSULES | Sourceable in Canada |
| KNIGHT THERAPEUTICS INC. | 8 | 8 | EXELON, EXELON PATCH 10, EXELON PATCH 15, EXELON PATCH 5 | Sourceable in Canada |
| APOTEX INC | 4 | 4 | APO-RIVASTIGMINE | Sourceable in Canada |
| GENERIC MEDICAL PARTNERS INC | 4 | 4 | MED-RIVASTIGMINE | Sourceable in Canada |
| MYLAN PHARMACEUTICALS ULC | 6 | 2 | MYLAN-RIVASTIGMINE, MYLAN-RIVASTIGMINE PATCH 10, MYLAN-RIVASTIGMINE PATCH 5 | Sourceable in Canada |
| SANDOZ CANADA INCORPORATED | 6 | 2 | SANDOZ RIVASTIGMINE, SANDOZ RIVASTIGMINE PATCH 10, SANDOZ RIVASTIGMINE PATCH 5 | Sourceable in Canada |
| PHARMASCIENCE INC | 6 | 0 | PMS-RIVASTIGMINE, RIVASTIGMINE PATCH 15, RIVASTIGMINE PATCH 5 | No marketed DIN |
| AURO PHARMA INC | 4 | 0 | AURO-RIVASTIGMINE | No marketed DIN |
| DOMINION PHARMACAL | 4 | 0 | DOM-RIVASTIGMINE | No marketed DIN |
| DR REDDY'S LABORATORIES LTD | 4 | 0 | RIVASTIGMINE TARTRATE CAPSULES | No marketed DIN |
| MINT PHARMACEUTICALS INC | 4 | 0 | MINT-RIVASTIGMINE | No marketed DIN |
| TEVA CANADA LIMITED | 4 | 0 | RATIO-RIVASTIGMINE | No marketed DIN |
Health Canada’s Drug Product Database does not flag which listing is the originator and which are subsequent-entry products, so Nexara does not label them here. Interchangeability is determined provincially, not federally — confirm for your province before a formulary switch. Nexara can confirm which of these is actually obtainable, and on what lead time, per order.
How is it supplied and stored?
Pack configuration, storage class and the handling constraints that drive cold-chain planning. One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced.
| Strength on the label | Strength |
|---|---|
| Dosage form | Patch |
| Route | Transdermal |
| Pack configuration (monograph) | Cartons of 30 individually sealed pouches. |
| Storage | Store at 15-30°C. (Note: General storage section 11 referenced, standard room temperature implied). |
Before an order line is unambiguous Nexara needs the strength, the pack size and the presentation.
Substance and classification
| Active substance | Rivastigmine |
|---|---|
| ATC code | N06DA03 |
| Biosimilar biologic | No |
Health Canada record and identifiers
The regulatory facts straight from the Drug Product Database, plus every identifier form Nexara accepts on a purchase order. A DIN written without its leading zeros is the commonest reason an order line fails to match.
| DIN (8-digit, as used in ordering) | 02479559 |
|---|---|
| DIN (unpadded, as printed on some documents) | 2479559 |
| Brand name | RIVASTIGMINE PATCH 10 |
| Generic / active ingredient | Active ingredient(s) See footnote 8 : Strength RIVASTIGMINE : 9.5 MG / 24 HOUR |
| Market authorization holder | PHARMASCIENCE INC 100 6111 Royalmount Ave Montreal Quebec Canada H4P 2T4 |
| Health Canada schedule | PRESCRIPTION |
| ATC code | N06DA03 |
| ATC anatomical main group | N — Nervous system |
| ATC therapeutic subgroup | N06DA |
| Current status | DORMANT |
| Status date | 31-Jul-2024 |
| Original market date | 2021-04-15 |
| Status source | Live Health Canada DPD sync |
Verify on the primary sources
How is it administered?
Apply one patch every 24 hours. Start with 4.6 mg/24h (Patch 5). Titrate to 9.5 mg/24h (Patch 10) after 4 weeks. 13.3 mg/24h (Patch 15) may be considered for moderately severe AD.
Included because it drives pack selection and wastage. Consult the monograph.
Contraindications
Hypersensitivity to rivastigmine or carbamates; severe liver impairment; history of application site reactions (allergic contact dermatitis); history of QT prolongation, torsade de pointes, or arrhythmias.
Warnings and precautions
Serious risk of overdose if more than one patch is worn. Remove previous patch before applying new one. Monitor for GI effects, weight loss, and severe skin reactions. Avoid external heat sources.
What can be used instead?
Alternatives on every axis a buyer actually considers — the same molecule in another presentation, the same class, an adjacent class, or a fixed-dose combination. Every row is led by the marketed DIN count, because that is what can be bought this week.
1 · Same molecule, other Canadian presentations
28 of 80 Canadian DINs for this molecule are currently marketed. Marketed products are listed first.
| Product | Strength | Form | Holder | Health Canada status | DIN |
|---|---|---|---|---|---|
| APO-RIVASTIGMINE | 3 MG | CAPSULE | APOTEX INC | MARKETED | 02336723 |
| APO-RIVASTIGMINE | 6 MG | CAPSULE | APOTEX INC | MARKETED | 02336758 |
| APO-RIVASTIGMINE | 1.5 MG | CAPSULE | APOTEX INC | MARKETED | 02336715 |
| APO-RIVASTIGMINE | 4.5 MG | CAPSULE | APOTEX INC | MARKETED | 02336731 |
| EXELON | 4.5 MG | CAPSULE | KNIGHT THERAPEUTICS INC. | MARKETED | 02242117 |
| EXELON | 1.5 MG | CAPSULE | KNIGHT THERAPEUTICS INC. | MARKETED | 02242115 |
| EXELON | 2 MG | SOLUTION | KNIGHT THERAPEUTICS INC. | MARKETED | 02245240 |
| EXELON | 3 MG | CAPSULE | KNIGHT THERAPEUTICS INC. | MARKETED | 02242116 |
| EXELON | 6 MG | CAPSULE | KNIGHT THERAPEUTICS INC. | MARKETED | 02242118 |
| EXELON PATCH 10 | 9.5 MG / 24 HOUR | PATCH | KNIGHT THERAPEUTICS INC. | MARKETED | 02302853 |
2 · Same class — other molecules in ATC N06DA
| Molecule | Canadian brands | DINs | Marketed | Sourceable |
|---|---|---|---|---|
| Donepezil | ACCEL-DONEPEZIL · ACH-DONEPEZIL · ACT DONEPEZIL · ACT DONEPEZIL ODT · +30 more | 76 | 37 | Yes |
| Rivastigmine | ACT RIVASTIGMINE PATCH 10 · ACT RIVASTIGMINE PATCH 5 · APO-RIVASTIGMINE · AURO-RIVASTIGMINE · +25 more | 80 | 28 | Yes |
| Galantamine | APO-GALANTAMINE · AURO-GALANTAMINE ER · GALANTAMINE ER · IPG-GALANTAMINE ER · +13 more | 46 | 12 | Yes |
A molecule with zero marketed DINs cannot be sourced domestically, however many approvals it holds — if one of these sits on a formulary or in an older protocol, that is the line to check.
3 · Adjacent classes in ATC N06D
| ATC subgroup | Molecules | DINs | Marketed |
|---|---|---|---|
| N06DX | Memantine | 21 | 9 |
Not clinical advice. These tables describe what can be supplied in Canada, not what should be prescribed. Substitution within or across classes is a prescriber and pharmacist decision, and interchangeability is determined provincially.
What else is RIVASTIGMINE PATCH 10 called?
The same molecule, Rivastigmine, is registered under other names elsewhere. Buyers and prescribers searching from outside Canada — or working from a foreign prescription or tender document — often know it by one of these:
| Name | Script | Registered in |
|---|---|---|
| Exelon | Latin | Australia, Bahrain, Czechia, South Africa |
| NIMVASTID | Latin | Czechia |
| Zeyzelf | Latin | Saudi Arabia |
Names are taken from national medicine registers and published price lists. A product registered abroad is not authorized for sale in Canada unless it holds its own DIN; import is possible only through the routes Health Canada permits.
How can I get it?
This DIN is dormant — it holds a Health Canada authorization but is not currently being marketed in Canada, so it cannot simply be ordered from Canadian stock. Where a patient need exists, supply may be possible through exceptional importation or the Special Access Programme, subject to Health Canada's requirements and the prescriber's application. Nexara can advise on the route and on marketed alternatives.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address. Patients and unlicensed buyers are routed to a partner pharmacy.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Why is there no price on this page?
Nexara quotes a delivered Canadian price per order, against a verified licence. Foreign list prices are published on incompatible bases and are not a guide to what any buyer can obtain here, so this page shows which markets list the molecule and on what basis, and nothing more.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.